Marvel Biosciences Selects Adelaide Site for Planned MB-204 Phase I Study
Marvel Biosciences selected CMAX in Adelaide, Australia, as the site for its planned first-in-human study of MB-204. The study is subject to regulatory and ethics approvals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.